ATR inhibitor

This page covers all ATR inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting ATR.

Targets

ATR

Phase 1 pipeline (1)

• Administration of ceralasertib monotherapy · AstraZeneca · Oncology
  Ceralasertib is an ATP-competitive inhibitor of the serine/threonine kinase ATR, which is involved in DNA damage response pathways.